Short-coated dogs with allergic skin disease

Mom and puppy Vizsla dogs
Study Title:
Safety and efficacy of a piperidine-based, reversible inhibitor of acetylcholinesterase in client-owned dogs with atopic dermatitis
Current Status: Open and enrolling
Principal Investigator: Sheila Torres, DVM, MS, PhD, DACVD
Contacts: Dr. Torres: torre009@umn.edu
Andrea Eckert, Senior Research Study Technician, aleckert@umn.edu, 612-625-3157

Study purpose:

Canine atopic dermatitis (AD) is a common chronic allergic skin condition that often causes severe itching and is difficult to manage. Many of the treatments we have today have undesirable side effects and others do not manage the symptoms completely. This clinical study will evaluate the safety and efficacy of a topical gel for dogs with atopic dermatitis.

Eligible dogs:

  • Short hair coat
  • Red and inflamed skin especially on belly, and/or paws
  • Demonstrated level of itching (chewing, scratching, licking, rubbing or rolling)
  • Age 12 months or older, not intended for breeding, not lactating
  • Non-seasonal environmental-induced AD
  • Cannot have cancer, mange, hypothyroidism, hyperadrenocorticism, dermatophytosis or autoimmune skin disorders
  • Cannot have bacterial or fungal infection
  • Will not have any abnormalities in pretreatment blood counts, serum chemistry or urinalysis

Study summary:

This is a 14-day study with visits on Day 0, 7 and 14. Owners will use a topical gel on selected areas of the skin once a day and will keep a medication diary at home. At the study visits, Dr. Torres will perform exams and assessments. Blood samples will be taken at each visit and urine samples on Day 0 and 14.

Costs of the study:

All study visits are paid by the study. In addition, at the conclusion of the 14-day study, owners will be eligible for a $200 debit card for their time and trouble.

To learn more, or to enroll, please contact Andrea Eckert or Dr. Torres (above).